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Primary central nervous system (CNS) melanoma is a type of rare and aggressive tumor that can easily spread to
the leptomeninges, and in fact, leptomeningeal metastasis is one of the most serious complications in patients with
this carcinoma. Prognosis is extremely poor if a CNS melanoma has metastasized, and there are no effective
treatments. Here, we present a case of a 37-year-old woman who presented with horizontal diplopia and progressive
headache. Magnetic resonance imaging findings were consistent with the diagnosis of melanoma. The results of
cytological examination of cerebrospinal fluid (CSF) showed malignant cells characteristic of melanoma. No extracranial
lesions were observed. All of the available evidence confirmed a diagnosis of leptomeningeal metastases from a
primary CNS melanoma. The patient received aggressive treatment, which consisted of concurrent radiotherapy
and weekly intra-CSF methotrexate (MTX) followed by adjuvant monthly intra-CSF MTX. Her survival time was
13 months after diagnosis. This case report suggests that the modality of concurrent radiotherapy and weekly
intra-CSF MTX followed by adjuvant monthly intra-CSF MTX may be used as the mainstay of treatment for such patients.
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Primary central nervous system (CNS) melanoma is an
uncommon disease and represents only 1% of all cases
of melanoma [1] and 0.07% of all brain tumors [2]. Me-
lanoblasts, the precursors of melanocytes, are of neural
crest origin, and during development they migrate to the
skin, uvea, mucous membranes and leptomeninges of
the CNS. Primary CNS melanoma is thought to arise
once melanocytes become neoplastic [3]. Because of its
histogenetic characteristics, it frequently metastasizes to
the leptomeninges, representing one of the most serious
complications for cancer patients. Although a subset of
patients with leptomeningeal metastases, particularly
those with lymphoma or breast cancer, may survive for
more than 12 months with a reasonable quality of life,
leptomeningeal metastasis from solid tumors such as
melanoma is associated with very poor prognosis. At* Correspondence: drlhdong@163.com
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but is not associated with a significant increase in
survival, and at best is only palliative [4].Case presentation
A 37-year-old woman was referred to our hospital
because of horizontal diplopia and progressive headache
for 2 weeks. She had a medical history of non-frequent
epilepsy as a child. Scattered melanocytic nevi with hair
were observed on her skin when she was born, without
darkened color, enlargement, pruritus or ulceration.
Neurological examination on admission revealed right
eye abduction. No other focal neurological signs, such as
abnormal reflexes, sensory deficits or neck stiffness,
were noted.
Cranial computed tomography (CT) scans revealed an
isodense or slight hyperdense lesion (CT value: 45 to 61)
in the left temporal lobe (Figure 1A). Magnetic reson-
ance imaging (MRI) of the brain demonstrated a 6-mm
abnormal signal with paramagnetic qualities in the
left temporal lobe, which shortened both T1 and T2
relaxation times. It was manifested as hyperintense. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Imaging findings for brain. (A) Computed tomography image showing an isodense or slightly hyperdense lesion in the left temporal
lobe (CT value: 45 to 61). Magnetic resonance image showing a 6-mm abnormal signal in the left temporal lobe, which was hyperintense on
T1-weighted images (B), hypointense on T2-weighted images (C), slightly hyperintense on fluid-attenuated inversion recovery images (D), and
mild enhancement with gadolinium contrast (E). Punctate and linear enhancement in the sulci and gyri of the cerebellum can be observed (F).
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T2-weighted images (Figure 1C) and slightly hyperin-
tense on fluid-attenuated inversion recovery images
(Figure 1D), with mild enhancement with gadolinium
contrast (Figure 1E). In addition, slightly hyperintense
signals in the sulci and gyri of the bilateral frontotemporal
lobe as well as punctate and linear enhancement in the
sulci and gyri of the cerebellum were observed (Figure 1F).
She also underwent chest and abdominal CT, which
showed no abnormalities.A non-traumatic lumbar puncture was performed. The
macroscopic appearance of the cerebrospinal fluid (CSF)
was hematic and cloudy, and the opening pressure was
30.4 mmHg (5 to 15 mmHg). Biochemical analysis of
the CSF revealed that the glucose level was 28.8 mg/dL
(41.4 to 73.8) and the protein level was 66 mg/dL (15 to
45). The cells consisted of leucocytes (15 cells/mm3) and
erythrocytes (110 cells/mm3). Malignant cells with the
characteristics of melanoma were found by cytological
examination of the CSF (Figure 2). No bacteria, viruses,
Figure 2 Malignant melanoma cells in the cerebral spinal fluid. (A, B) Round or oval tumor cells with different sizes were scattered, and
presented as pseudopodia-like protrusions on cell membranes, with basophilic characteristics. Cells had round nuclei, large and distinct nucleoli,
coarse and unevenly distributed chromatin, and particles in the nucleus or cytoplasm. (Liquid-based cytology, Papanicolaou staining, ×400).
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detected in the CSF.
The patient received aggressive treatment including
concurrent whole brain radiotherapy (linear accelerator,
6 MV photon beam, 40 Gy in 20 fractions) and intra-
CSF chemotherapy. Methotrexate (MTX) 15 mg and
dexamethasone 5 mg were given intrathecally once weekly
from the second day of radiotherapy, for a total of
8 weeks. On the eighth administration of intra-CSF
MTX, CSF examination showed that the opening pressure
was 18.2 mmHg, with a colorless transparent appearance.
The glucose and protein levels were 28.8 mg/dL and
18.5 mg/dL, respectively. Cellular components con-
sisted of leucocytes (20 cells/mm3) and erythrocytes
(10 cells/mm3). No malignant cells were found in the
CSF. Symptomatically, the patient was in complete remis-
sion. No severe treatment-related adverse events were
noted, and her memory and cognitive ability had not obvi-
ously changed before and after treatment. Thereafter, it
was suggested that she undergo monthly intra-CSF MTX.
However, the patient herself refused the treatment on the
fifth month. Headache and vomiting reappeared, but re-
solved following intra-CSF MTX (15 mg) monthly. Treat-
ment was again interrupted until month 9, and recurrence
was noted. She refused any examinations including brain
MRI and CSF analysis. Unfortunately, re-administration of
intra-CSF MTX was ineffective. The patient died from
progression of the nervous system disease at 13 months
after initial presentation with diplopia.
Discussion
It seems reasonable that malignant melanoma can
occur in any organ in which melanoblasts can normally
be found. This includes the pia mater, skin and uvea.
However, primary CNS melanoma is thought to be an
uncommon pathology. It can be divided into two
forms. The first invades the meninges diffusely, while
the second causes nodular intraparenchymal lesions.
There are frequent literature reports regarding melan-
oma of the nervous system, but in some cases it is noteasy to differentiate the primary tumor from metastatic
disease. Prognosis is extremely poor, especially in the
presence of leptomeningeal metastasis. There are no
effective treatments. To our knowledge, this is the first
case of a patient receiving aggressive treatment that
consisted of concurrent radiotherapy and weekly intra-
CSF MTX followed by adjuvant monthly intra-CSF
MTX. This treatment modality gave a relatively long
survival time.
In contrast to brain metastases, which usually occur in
the junction between gray and white matter, intrapar-
enchymal nodular lesions of primary melanomas may
occur in the brain at any leptomeningeal location [5].
The tumor in the present patient was located in the left
temporal lobe adjacent to the Sylvian fissure close to the
leptomeninges. This was consistent with the developing
characteristics of primary CNS melanoma. The imaging
features of the primary CNS melanoma were unique.
Typically, a melanoma appears hyperdense on unen-
hanced CT, and after intravenous administration of io-
dinated contrast medium, uniform or ring enhancement
is generally observed [1]. The MRI signal of a melanoma
in the CNS depends on several factors. Studies of meta-
static melanomas have demonstrated a trend toward
shorter T1 and T2 relaxation times, with increasing
melanin content ascribed to the paramagnetic effect of
melanin [6], as demonstrated in the present case. These
characteristics are not seen in other intracranial tumors,
and can be used to confirm diagnosis [7]. In addition,
spontaneous hemorrhage is frequently reported in mel-
anoma because the tumor is rich in blood vessels, and
can easily invade the vessels of the meninges, which also
has a suggestive role in diagnosis [8].
CSF cytology may provide an important basis for
diagnosis of leptomeningeal melanoma. The melanocytes
present in the CSF appear uneven in size, with baso-
philia and an increased nucleocytoplasmic ratio. They
are multinuclear and there are irregular pseudopodial
apophyses on the cytomembrane. All of these are
specific characteristics of melanoma cells.
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of cutaneous melanocytes and are usually defined as
melanocytic lesions present at birth [9]. Individuals with
congenital melanocytic nevi are at high risk of develop-
ing malignant melanoma [10,11]. About 25% of patients
with primary CNS melanoma have been reported to
have congenital melanocytic nevi [12]. To render a diag-
nosis of primary CNS melanoma, there must be no evi-
dence of the lesion elsewhere [13,14]. The melanocytic
nevi in the present patient were observed when she was
born, but no signs of malignancy were found. In addition,
no extracranial lesions were observed from the onset of
disease to death. All of the available evidence confirmed a
diagnosis of primary CNS melanoma.
Primary CNS melanoma is an aggressive type of tumor
that may metastasize to other organs. Total resection or
radiotherapy is the primary treatment for patients with
local intraparenchymal lesions [1,5], and may be associ-
ated with relatively long survival [15,16]. However, the
prognosis of metastatic leptomeningeal melanoma is very
poor because of complete CNS involvement by tumor
cells. Harstad et al. conducted a study with 110 patients
with metastatic leptomeningeal melanoma and reported
that the overall median survival was 10 weeks [17]. Intra-
CSF chemotherapy, as a treatment modality for the CNS,
can kill tumor cells in the CSF directly, and is the primary
treatment for leptomeningeal neoplasms. MTX is the
most effective drug used in intra-CSF chemotherapy for
leptomeningeal metastases from solid tumors including
melanoma [18]. The total CSF volume is 100 to 150 mL,
and 10 to 15 mg of MTX once or twice weekly can be
considered an effective cytotoxic concentration in the CSF
[19]. The corticosteroids used in intra-CSF chemotherapy
can effectively reduce the incidence of chemical meningi-
tis and relieve nervous system toxicity induced by chemo-
therapeutic agents [19].
Involved-field radiotherapy at sites of symptomatic
or bulky disease is an important treatment modality for
the majority of patients with leptomeningeal neoplasm.
Paolo et al. documented a patient with advanced melan-
oma and multiple metastases harboring the V600EBRAF
mutation, who underwent treatment with BRAF inhibi-
tors [20]. The patient progressively deteriorated and died
of leptomeningeal metastasis. However, another case
presented by Lee et al. involved a patient with a similar
disease who received treatment with BRAF inhibitors
and whole brain radiotherapy (30 Gy in 10 fractions)
[21]. Remission of symptoms was achieved and long-
term survival was reported. These two distinct prog-
noses suggest that whole brain radiotherapy plays an
important role in the treatment of leptomeningeal
metastases. Radiotherapy in patients with cranial neuropa-
thies is also indicated to reestablish normal CSF cir-
culation to permit increased efficacy of intra-CSFchemotherapy, which has been shown to improve
outcomes [18].
Chamberlain and Kormanik carried out a phase II
study of combined modality therapy for leptomeningeal
metastases due to melanoma, which enrolled 16 patients
[22]. The majority of patients in that study underwent
intraventricular chemotherapy after completion of radio-
therapy. The overall survival of all patients was 2 to
8 months, with a median survival of 4 months; 75% of
patients died as a result of progressive leptomeningeal
metastases and/or systemic disease progression.
Based on previous studies, concurrent radiotherapy
and intra-CSF chemotherapy were chosen for the present
patient. Symptoms related to meningeal irritation were re-
lieved quickly, and the patient survived for more than one
year. No severe toxicity was observed. The therapeutic ad-
vantages of the present treatment modality are as follows:
(1) MTX is an S-phase specific antineoplastic agent, and
tumor cells in the G2 and M phases are more sensitive to
radiotherapy than cells in other phases. Therefore, radio-
therapy combined with intra-CSF MTX may improve the
antitumor effects because of a synergistic effect on differ-
ent phases of the cell cycle. (2) MTX has a sensitizing
effect on radiotherapy [23]. (3) Whole brain radiotherapy
may break the blood–brain barrier, which improves CSF
circulation and is beneficial in distributing chemothera-
peutic agents in the CSF [24].Unfortunately, the patient
received sequential intra-CSF MTX at a local hospital
after disease progression. Therefore, it is unclear if survival
could have been further prolonged if the treatment had
been changed or if systemic chemotherapy had been
administered.
Conclusions
In general, primary CNS melanoma is a rare disease
associated with poor prognosis when the leptomeninges
are involved. The treatment modality of concurrent
radiotherapy and weekly intra-CSF MTX followed by
adjuvant monthly intra-CSF MTX may be an efficacious
combination. However, additional studies are needed to
improve treatment and prognosis.
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